Search global stocks & ETFs...Ctrl K

Learn Mode

LLY - Eli Lilly and Co

595

$1,006.70

-$9.05 (-0.891%)

At market close

$1,000.01

-$6.70 (-0.665%)

Pre Market 5/15/26, 11:31 AM

Score

4.66/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

LLY

Valuation Score

View as %

Stock Unlock

YTD

Max

Stock Profile

Market Cap

$948.05B

Industry

Pharmaceuticals

EPS (TTM)

$28.21

P/E (TTM)

37.51

Div & Yield

$6.92 (0.69%)

FCF Payout Ratio

62.86%

P/S (TTM)

13.12

P/B

30.39

Diluted Shares

895.90M

Ex-Dividend

2026-05-15

Next Earnings

08-05

Forward P/E

26.41

Payout Ratio

25.78%

P/FCF (TTM)

91.44

FCF Yield

1.09%

Earnings Yield

2.67%

52 Week Range

Score Card

Explore Scores Tab

4.66

Very Good

Eli Lilly and Co has grown revenue at 47.44% over the past year, which is strong growth. Also, it has seen its diluted average shares outstanding decrease by -0.52% over the past year, which suggests the company is buying back shares.

Valuation Model

Key Score

2.00

Bad

Management

5.00

Very Good

Growth

2.00

Bad

Profitability

3.00

Average

Fin. Health

5.00

Very Good

Dividends

1.00

Very Bad

Analyst

3.00

Average

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

1 new filing was in the last 7 days

Filter Form Types

Form SD

Specialized Disclosure Report

Filed on 2026-05-11 16:30:32

Form 424B2

Unknown Form Type

Filed on 2026-05-08 06:05:18

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-05-07 16:41:48

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-07 16:00:10

Form FWP

Unknown Form Type

Filed on 2026-05-06 17:25:04

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-05-06 16:35:55

Form 424B2

Unknown Form Type

Filed on 2026-05-06 08:04:50

Form SCHEDULE 13G

Unknown Form Type

Filed on 2026-05-01 08:38:53

Form 10-Q

General form for quarterly financial reports under Section 13 or 15(d)

Filed on 2026-04-30 11:25:48

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-04-30 07:03:30

Form PX14A6G

Notice of exempt solicitation submitted by non-management

Filed on 2026-04-29 13:18:31

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-21 16:20:53

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-04-25

High:

$1,575

56.5%

Avg:

$1,219

21.1%

Low:

$859

-14.7%

(% change is relative to the current stock price: $1,006.70)

Analyst Recommendations

Go to Analyst Tab

4.03

Good

28%

Strong Buy (11)

49%

Buy (19)

21%

Hold (8)

Sell (1)

Strong Sell (0)

About

Website
https://www.lilly.com/
Address
Lilly Corporate Ctr, Drop Code 1094, Indianapolis INDIANA, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=59478

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 50,000 full-time employees. The firm manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.

IPO Date

1970-07-09

Industry

Pharmaceuticals

Total Employees

50,000

Exchange

New York Stock Exchange, Inc.

Reporting Currency

USD

GICS

Pharmaceuticals

GICS Sub

Pharmaceuticals

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences

LLY - Eli Lilly and Co

595

$1,006.70

-$9.05 (-0.891%)

$1,000.01

-$6.70 (-0.665%)

4.66/5

Stock Unlock

Stock Profile

Score Card

Very Good

Insider Transactions

Market News

Form SD

Filed on 2026-05-11 16:30:32

Form 424B2

Filed on 2026-05-08 06:05:18

Form 8-K

Filed on 2026-05-07 16:41:48

Form 4

Filed on 2026-05-07 16:00:10

Form FWP

Filed on 2026-05-06 17:25:04

Form 144

Filed on 2026-05-06 16:35:55

Form 424B2

Filed on 2026-05-06 08:04:50

Form SCHEDULE 13G

Filed on 2026-05-01 08:38:53

Form 10-Q

Filed on 2026-04-30 11:25:48

Form 8-K

Filed on 2026-04-30 07:03:30

Form PX14A6G

Filed on 2026-04-29 13:18:31

Form 4

Filed on 2026-04-21 16:20:53

Financials

Price Targets

56.5%

21.1%

-14.7%

Analyst Recommendations

About

Similar Stocks